BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22372889)

  • 1. Synthesis and assessment of globotriose-chitosan conjugate, a novel inhibitor of shiga toxins produced by Escherichia coli.
    Li X; Wu P; Cheng S; Lv X
    J Med Chem; 2012 Mar; 55(6):2702-10. PubMed ID: 22372889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
    Watanabe M; Matsuoka K; Kita E; Igai K; Higashi N; Miyagawa A; Watanabe T; Yanoshita R; Samejima Y; Terunuma D; Natori Y; Nishikawa K
    J Infect Dis; 2004 Feb; 189(3):360-8. PubMed ID: 14745692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
    Nishikawa K; Matsuoka K; Kita E; Okabe N; Mizuguchi M; Hino K; Miyazawa S; Yamasaki C; Aoki J; Takashima S; Yamakawa Y; Nishijima M; Terunuma D; Kuzuhara H; Natori Y
    Proc Natl Acad Sci U S A; 2002 May; 99(11):7669-74. PubMed ID: 12032341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
    Nishikawa K
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):239-47. PubMed ID: 21644029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ampicillin, gentamicin, and cefotaxime on the release of Shiga toxins from Shiga toxin-producing Escherichia coli isolated during a diarrhea episode in Faisalabad, Pakistan.
    Mohsin M; Haque A; Ali A; Sarwar Y; Bashir S; Tariq A; Afzal A; Iftikhar T; Saeed MA
    Foodborne Pathog Dis; 2010 Jan; 7(1):85-90. PubMed ID: 19785532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
    Orth D; Grif K; Khan AB; Naim A; Dierich MP; Würzner R
    Diagn Microbiol Infect Dis; 2007 Nov; 59(3):235-42. PubMed ID: 17931818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission].
    Rivas M; Miliwebsky E; Chinen I; Deza N; Leotta GA
    Medicina (B Aires); 2006; 66 Suppl 3():27-32. PubMed ID: 17354474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An epidemiologic surveillance of Shiga-like toxin-producing Escherichia coli infection in Argentinean children: risk factors and serum Shiga-like toxin 2 values.
    López EL; Contrini MM; Glatstein E; Ayala SG; Santoro R; Ezcurra G; Teplitz E; Matsumoto Y; Sato H; Sakai K; Katsuura Y; Hoshide S; Morita T; Harning R; Brookman S
    Pediatr Infect Dis J; 2012 Jan; 31(1):20-4. PubMed ID: 21829137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.
    Cornick NA; Jelacic S; Ciol MA; Tarr PI
    J Infect Dis; 2002 Jul; 186(1):57-63. PubMed ID: 12089662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.
    Sheoran AS; Dmitriev IP; Kashentseva EA; Cohen O; Mukherjee J; Debatis M; Shearer J; Tremblay JM; Beamer G; Curiel DT; Shoemaker CB; Tzipori S
    Infect Immun; 2015 Jan; 83(1):286-91. PubMed ID: 25368111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11.
    Misselwitz J; Karch H; Bielazewska M; John U; Ringelmann F; Rönnefarth G; Patzer L
    Pediatr Infect Dis J; 2003 Apr; 22(4):349-54. PubMed ID: 12690276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shiga toxin activatable by intestinal mucus in Escherichia coli isolated from humans: predictor for a severe clinical outcome.
    Bielaszewska M; Friedrich AW; Aldick T; Schürk-Bulgrin R; Karch H
    Clin Infect Dis; 2006 Nov; 43(9):1160-7. PubMed ID: 17029135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial resistance of Shiga toxin (verotoxin)-producing Escherichia coli O157:H7 and non-O157 strains isolated from humans, cattle, sheep and food in Spain.
    Mora A; Blanco JE; Blanco M; Alonso MP; Dhabi G; Echeita A; González EA; Bernárdez MI; Blanco J
    Res Microbiol; 2005 Aug; 156(7):793-806. PubMed ID: 15921895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiological investigation of Shiga toxin-producing Escherichia coli isolates originated from healthy sheep in one farm of Jiangsu Province and their pathogenicity].
    Gu C; Xue T; Xu T; Gao S; Jiao X; Liu X
    Wei Sheng Wu Xue Bao; 2011 May; 51(5):676-83. PubMed ID: 21800631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.
    Johnson KE; Thorpe CM; Sears CL
    Clin Infect Dis; 2006 Dec; 43(12):1587-95. PubMed ID: 17109294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-O157 Shiga toxin-producing Escherichia coli infections in the United States, 1983-2002.
    Brooks JT; Sowers EG; Wells JG; Greene KD; Griffin PM; Hoekstra RM; Strockbine NA
    J Infect Dis; 2005 Oct; 192(8):1422-9. PubMed ID: 16170761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
    Müthing J; Schweppe CH; Karch H; Friedrich AW
    Thromb Haemost; 2009 Feb; 101(2):252-64. PubMed ID: 19190807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid and sensitive detection of Shiga toxin-producing Escherichia coli directly from stool samples by real-time PCR in comparison to culture, enzyme immunoassay and Vero cell cytotoxicity assay.
    Gerritzen A; Wittke JW; Wolff D
    Clin Lab; 2011; 57(11-12):993-8. PubMed ID: 22239032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection.
    Wickham ME; Lupp C; Mascarenhas M; Vazquez A; Coombes BK; Brown NF; Coburn BA; Deng W; Puente JL; Karmali MA; Finlay BB
    J Infect Dis; 2006 Sep; 194(6):819-27. PubMed ID: 16941350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.
    Friedrich AW; Bielaszewska M; Zhang WL; Pulz M; Kuczius T; Ammon A; Karch H
    J Infect Dis; 2002 Jan; 185(1):74-84. PubMed ID: 11756984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.